<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156733">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01059344</url>
  </required_header>
  <id_info>
    <org_study_id>TP0203</org_study_id>
    <nct_id>NCT01059344</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis</brief_title>
  <official_title>A Randomized Placebo-Controlled Double-Blind Study to Evaluate the Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tillotts Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tillotts Pharma AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Asacol™ 4.8 g/day (800 mg tablets) is statistically significant more effective to induce
      clinical and endoscopic remission after 6 weeks of treatment compared to placebo in subjects
      with active ulcerative colitis (UC).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of the study is to determine the efficacy of Asacol™ 4.8 g/day (800 mg tablets) to induce clinical and endoscopic remission after 6 weeks of treatment compared to placebo in subjects with active ulcerative colitis (UC).</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>▪ the proportion of subjects achieving clinical and endoscopic remission at both Week 6 and Week 10 ▪ the proportion of subjects achieving clinical remission at Week 6 ▪ the proportion of subjects achieving clinical improvement at Week 6</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">281</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Mesalamin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesalamin</intervention_name>
    <description>4.8g/day, 800 mg tablets</description>
    <arm_group_label>Mesalamin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Asacol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        (1) Male or non-pregnant, non-lactating females, 18 years of age or older. (2) Documented
        diagnosis of UC with disease extending at least 15 cm from the anal verge.

        (3) Active UC defined by:

        (a) modified UC-DAI score of 4-10 with (b) sigmoidoscopy component score ≥ 2 and (c)
        rectal bleeding component score ≥ 1 (4) Ability of subject to participate fully in all
        aspects of this clinical trial.

        (5) Written informed consent must be obtained and documented.

        Exclusion Criteria:

          1. Severe UC defined by the following criteria:

             ³6 bloody stools daily with one or more of the following:

               1. oral temperature &gt; 37.8°C or &gt; 100.0°F

               2. pulse &gt; 90/min

               3. hemoglobin &lt; 10 g/dL

          2. Previously failed treatment with a mesalazine dose of &gt; 2.0 g/day.

          3. Current relapse lasting &gt; 6 weeks in the opinion of the investigator.

          4. Treatment with 5-ASA at a dose of &gt;2.0g/day within 1 week prior to randomisation

          5. Treatment with systemic or rectal steroids within 4 weeks prior to randomization.

          6. Treatment with immunosuppressants within 6 weeks prior to randomization.

          7. Treatment with infliximab or other biologics within 3 months prior to randomization.

          8. Treatment with systemic antibiotics for UC within 7 days prior to randomization.

          9. Treatment with probiotics within 7 days prior to randomization.

         10. Treatment with anti-diarrheals within 7 days prior to randomization.

         11. Treatment with nicotine patch within 7 days prior to randomization.

         12. Received any investigational drug within 30 days prior to randomization.

         13. History of colectomy or partial colectomy.

         14. History of definite dysplasia in colonic biopsies.

         15. Crohn's disease.

         16. Known bleeding disorders.

         17. Immediate or significant risk of toxic megacolon.

         18. Hypersensitivity to salicylates, aspirin, sulfasalazine or 5-ASA.

         19. Serum creatinine &gt; 1.5 times the upper limit of the normal range.

         20. AST, ALT, total bilirubin or alkaline phosphatase &gt; 2 times the upper limit of the
             normal range.

         21. Serious underlying disease other than UC which in the opinion of the investigator may
             interfere with the subject's ability to participate fully in the study.

         22. History of alcohol or drug abuse which in the opinion of the investigator may
             interfere with the subject's ability to comply with the study procedures.

         23. Stools positive for clostridium difficile.

         24. Pregnant or lactating women.

         25. Prior enrolment in the current study and had received study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Feagan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Robarts Clinical Trials</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gomel Regional Clinical Hospital, 9</name>
      <address>
        <city>Gomel</city>
        <zip>23602</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital No.1</name>
      <address>
        <city>Minsk</city>
        <zip>220013</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minsk Regional Clinical Hospital, 41</name>
      <address>
        <city>Minsk</city>
        <zip>2230</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital No. 2</name>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>E.Klumov City Clinical Hospital No. 3</name>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitebsk Regional Clinical Hospital</name>
      <address>
        <city>Vitebsk</city>
        <zip>210037</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medwin Hospital</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhrapradesh</state>
        <zip>500 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osmania General Hospital</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhrapradesh</state>
        <zip>500 012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.S.Ramiah Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shree Gokulam Medical College and Research Foundation</name>
      <address>
        <city>Trivandrum</city>
        <state>Kerala</state>
        <zip>695 607</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S. R. Kalla Memorial Gastro and General Hospital</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Life Line Hospital</name>
      <address>
        <city>Chennai</city>
        <state>TamilNadu</state>
        <zip>600 096</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maulana Azad Medical College and Associated Lok Nayak Hospital</name>
      <address>
        <city>New Delhi</city>
        <zip>110 002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of liver and billiary sciences</name>
      <address>
        <city>New Delhi</city>
        <zip>110 070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gazi University Medical Faculty Besevler</name>
      <address>
        <city>Besevler-Ankara</city>
        <zip>06500</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dicle University Medical Faculty</name>
      <address>
        <city>Diyarbakir</city>
        <zip>21280</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trakya University Medical Faculty</name>
      <address>
        <city>Edirne</city>
        <zip>22030</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gaziantep University Medical Faculty Kampus Alani</name>
      <address>
        <city>Gaziantep</city>
        <zip>27310</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylul University Medical Faculty Inciralti</name>
      <address>
        <city>Inciralti-Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sisli Etfal Egitim ve Arastirma Hospital Sisli</name>
      <address>
        <city>Istanbul</city>
        <zip>34360</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ataturk Egitim ve Arastirma Hospital Basin Sitesi</name>
      <address>
        <city>Izmir</city>
        <zip>35360</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara University Medical Faculty Sihhiye</name>
      <address>
        <city>Sihhiye-Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe University Medical Faculty Sihhiye</name>
      <address>
        <city>Sihhiye-Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dnipropetrovska derzhavna medychna akademiia,</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>4904</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankivskyi natsionalnyi medychnyi universytet,</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miska klinichna likarnia 2,</name>
      <address>
        <city>Kharkiv</city>
        <zip>61001</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Natsionalnyi medychnyi universytet im. Bogomoltsia, kafedra khirurgii 1 na bazi viddilennia proctologii Miskoi klinichnoi likarni 18, m.Kyiv</name>
      <address>
        <city>Kyiv</city>
        <zip>01030</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Natsionalnyi medychnyi universytet im. O.O. Bogomoltsia,</name>
      <address>
        <city>Kyiv</city>
        <zip>04053</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Natsionalna medychna akademia pisliadyplomnoi osvity im. P.L. Shupyk,</name>
      <address>
        <city>Kyiv</city>
        <zip>04201</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lvivskyi natsionalnyi medychnyi universytet imeni Danyla Galytskogo,</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odeska oblasna klinichna likarnia, Oblasnyi tsentr gastroenterologii,</name>
      <address>
        <city>Odessa</city>
        <zip>65039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>India</country>
    <country>Turkey</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>September 16, 2013</lastchanged_date>
  <firstreceived_date>January 28, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mesalamine</keyword>
  <keyword>Asacol</keyword>
  <keyword>Ulcerative colitis</keyword>
  <keyword>induction therapy</keyword>
  <keyword>acute disease</keyword>
  <keyword>mild to moderate</keyword>
  <keyword>Active Ulcerative Colitis (mild to moderate)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Colitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
